Accessibility navigation


Cardiac effects of 6 months’ dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised-controlled, VASERA TRIAL

Faconti, L., Mills, C. E., Govoni, V., Gu, H., Morant, S., Jiang, B., Cruickshank, J. K. and Webb, A. J. (2019) Cardiac effects of 6 months’ dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised-controlled, VASERA TRIAL. British Journal of Clinical Pharmacology, 85 (1). pp. 169-180. ISSN 0306-5251

[img] Text - Accepted Version
· Restricted to Repository staff only until 14 November 2019.

1MB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1111/bcp.13783

Abstract/Summary

Aims: To explore whether long-term intervention with dietary nitrate ((NO3-), a potential tolerance-free source of beneficial vasoactive nitric oxide) and spironolactone (to oppose aldosterone’s potential deleterious cardiovascular effects) improve cardiac structure/function, independent of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). Methods: A sub-sample of participants in our double-blind, randomised, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate-depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had trans-thoracic cardiac ultrasounds at baseline (n=105), 3 and 6 months (n=87) of intervention. Analysis was by modified intention-to-treat. Results: Nitrate-containing juice (n=40) decreased left ventricular (LV) end diastolic volume: -6.3 mL (95% confidence intervals (CI) -11.1,-1.6), and end systolic volume: -3.2 mL (-5.9,-0.5), and increased end diastolic mass/volume ratio: +0.04 (0.00,0.07), relative to placebo juice (n=47). Spironolactone (n=44) reduced relative wall thickness compared to doxazosin (n=43): -0.01 (-0.02,-0.00). Whilst spironolactone reduced LV mass index relative to baseline: -1.48 g/m2.7 (-2.08,-0.88), there was no difference versus doxazosin: -0.85 g/m2.7 (-1.76,0.05). Spironolactone also decreased the E/A ratio: -0.12 (-0.19,-0.04) and increased S’ (a tissue-Doppler systolic function index) by 0.52 (0.05,1.0 cm/s). BP did not differ between the juices, or between the drugs. Conclusions: 6 months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterised in pre-clinical models of heart failure. Spironolactone’s effects on cardiac remodeling and systo-diastolic function whilst confirmatory, were independent of BP.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Human Nutrition Research Group
ID Code:79051
Publisher:Wiley-Blackwell

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation